SCHEMBL30239130

SCHEMBL30239130

CN1Cc2nc3cc(C(=O)O)ccc3c(Cl)c2C1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
HPGD P15428 1/20 0.47
MAPT P10636 6/20 0.47
KMT2A Q03164 5/20 0.47
HTT P42858 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.45
POLB P06746 1/20 0.45
BLM P54132 1/20 0.45
SMYD3 Q9H7B4 3/20 0.44
MEN1 O00255 3/20 0.43
GAA P10253 1/20 0.43
GFER P55789 1/20 0.43
TP53 P04637 1/20 0.43
LMNA P02545 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30239064 0.90 ALDH1A1 (0.51) ALDH1A1NPC1RAB9AHPGDMAPT
SCHEMBL24931199 0.90 ALDH1A1 (0.51) ALDH1A1NPC1RAB9AHPGDMAPT
SCHEMBL30239149 0.90 ALDH1A1 (0.51) ALDH1A1NPC1RAB9AHPGDMAPT
SCHEMBL24931201 0.90 ALDH1A1 (0.51) ALDH1A1NPC1RAB9AHPGDMAPT
SCHEMBL30239625 0.86 NPC1 (0.49) ALDH1A1NPC1RAB9AMAPTKMT2A
SCHEMBL24931211 0.86 NPC1 (0.49) ALDH1A1NPC1RAB9AMAPTKMT2A
SCHEMBL30239120 0.81 ALDH1A1 (0.52) ALDH1A1NPC1RAB9AHPGDMAPT
SCHEMBL2218702 0.78 MAPT (0.72) ALDH1A1NPC1RAB9AHPGDMAPT
SCHEMBL2228741 0.77 MAPT (0.70) ALDH1A1NPC1RAB9AHPGDMAPT
SCHEMBL13822707 0.70 KMT2A (0.65) ALDH1A1NPC1RAB9AMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376076-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) DANA-FARBER CANCER INSTITUTE, INC. 2024-11-14 US disclosed
CN-118401507-A Inhibitors targeting ubiquitin-specific protease 7 (USP 7) 丹娜法伯癌症研究院 2024-07-26 CN disclosed
EP-4373816-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) Dana-Farber Cancer Institute, Inc. (US) 2024-05-29 EP disclosed
WO-2023003973-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376076-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) USP7, USP47, USP2 ALDH1A1 2692/4885NPC1 1511/4885RAB9A 1457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.